1398-9995/asset/olbannerleft.gif?v=1&s=2207070238298c1b0c4b1e73fa97140fa65e5f81)
1398-9995/asset/olbannerright.gif?v=1&s=c902da976bf6db24fc36ec0480207615a3d14921)
You have full text access to this OnlineOpen article
Nasal CpG oligodeoxynucleotide administration induces a local inflammatory response in nonallergic individuals
Article first published online: 20 FEB 2009
DOI: 10.1111/j.1398-9995.2009.02012.x
© 2009 John Wiley & Sons A/S
Additional Information
How to Cite
Månsson, A., Bachar, O., Adner, M. and Cardell, L.-O. (2009), Nasal CpG oligodeoxynucleotide administration induces a local inflammatory response in nonallergic individuals. Allergy, 64: 1292–1300. doi: 10.1111/j.1398-9995.2009.02012.x
Publication History
- Issue published online: 14 SEP 2009
- Article first published online: 20 FEB 2009
- Accepted for publication 29 January 2009
References
- 1, , , , , et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 2006;12:1023–1026.
- 2, , , , , et al. Influence of short-term exposure to airborne Der p 1 and volatile organic compounds on skin barrier function and dermal blood flow in patients with atopic eczema and healthy individuals. Clin Exp Allergy 2006;36:338–345.
- 3, , , , , et al. Eosinophil influx to the nasal airway after local, low-level LPS challenge in humans. J Allergy Clin Immunol 1999;104(2 Pt 1):388–394.
- 4, , , , . Cytokine release from the nasal mucosa and whole blood after experimental exposures to organic dusts. Eur Respir J 2000;16:140–145.Direct Link:
- 5, . Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003;85:85–95.
- 6, , , , . Lipopolysaccharide administration to the allergic nose contributes to lower airway inflammation. Clin Exp Allergy 2007;37:1773–1780.
- 7, , , . Structural requirements for uptake and recognition of CpG oligonucleotides. Int J Med Microbiol 2008;298:33–38.
- 8. Interactions between bacterial CpG–DNA and TLR9 bridge innate and adaptive immunity. Curr Opin Microbiol 2002;5:62–69.
- 9, , , , , et al. Expression of toll-like receptor 9 in nose, peripheral blood and bone marrow during symptomatic allergic rhinitis. Respir Res 2007;8:17.
- 10, , , , , et al. A toll-like receptor recognizes bacterial DNA. Nature 2000;408:740–745.
- 11. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004;4:249–258.
- 12, . Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs 2007;21:387–401.
- 13, , , , , et al. Cutting edge: role of toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 2001;167:3555–3558.
- 14, , . Psoriasin, one of several new proteins identified in nasal lavage fluid from allergic and non-allergic individuals using 2-dimensional gel electrophoresis and mass spectrometry. Respir Res 2005;6:118.
- 15, , . Repeatability of standardised nasal nitric oxide measurements in healthy and asthmatic adults and children. Respir Med 2005;99:1105–1114.
- 16, , , . Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant. Laryngoscope 2006;116:331–335.
- 17, . Contribution of microbial-associated molecules in innate mucosal responses. Cell Mol Life Sci 2005;62:1349–1358.
- 18, , , . Mucosal interplay among commensal and pathogenic bacteria: lessons from flagellin and toll-like receptor 5. FEBS Lett 2006;580:2976–2984.
- 19, , , , , . Immune responses induced by intranasal imiquimod and implications for therapeutics in rhinovirus infections. J Cell Mol Med 2005;9:457–461.
- 20, , , , , et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998;160:2555–2559.
- 21, , , , , et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol 1998;161:7054–7062.
- 22, , , , , et al. Immunostimulatory oligonucleotides attenuate airways remodeling in allergic monkeys. Am J Respir Crit Care Med 2004;170:1153–1157.
- 23, , , , , . Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol 1999;162:6284–6293.
- 24, , , , , et al. CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma. J Immunol 2000;165:5906–5912.
- 25, , , , , et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006;355:1445–1455.
- 26, , , , . Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. Am J Respir Crit Care Med 2006;174:15–20.
- 27, , . Increased nitric oxide in exhaled air of normal human subjects with upper respiratory tract infections. Eur Respir J 1995;8:295–297.
- 28
- 29, , , , . Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against non-typeable Haemophilus influenzae in the nasopharynx. Laryngoscope 2006;116:407–412.
- 30, , , , , . Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J Immunol 2001;166:3451–3457.
- 31, . CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol 1998;161:4463–4466.
- 32, , , , , et al. Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002;168:4531–4537.
- 33, , , , , et al. Analysis of plasmacytoid and myeloid dendritic cells in nasal epithelium. Clin Vaccine Immunol 2006;13:1278–1286.
- 34, , , , , et al. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol 2003;33:1633–1641.
- 35, , , . Activation of TLR-9 induces IL-8 secretion through peroxynitrite signaling in human neutrophils. J Immunol 2006;176:1195–1202.
- 36, , , . Expression of TLR9 in human nasal epithelial cells. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2008;22:356–358.
- 37, , , , , et al. Nasal cytokines in common cold and allergic rhinitis. Clin Exp Allergy 1995;25:166–172.
- 38, , , , , et al. IL-4-mediated fine tuning of IL-12p70 production by human DC. Eur J Immunol 2008;38:3138–3149.
- 39, , , , , et al. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J Exp Med 2000;192:823–833.
- 40, , , . Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells. J Exp Med 2005;201:1899–1903.
- 41, , , . Pituitary adenylate cyclase-activating polypeptide, effects in the human nose. Clin Exp Allergy 2003;33:942–949.
- 42, , , , , . Sinonasal epithelial cell expression of toll-like receptor 9 is decreased in chronic rhinosinusitis with polyps. Am J Rhinol 2007;21:110–116.
- 43, , , , , et al. Human epithelial cells establish direct antifungal defense through TLR4-mediated signaling. J Clin Invest 2007;117:3664–3672.
- 44. Anti-inflammatory cytokines in asthma and allergy: interleukin-10, interleukin-12, interferon-gamma. Mediators Inflamm 2001;10:51–59.
- 45. Minimal persistent inflammation, an emerging concept in the nature and treatment of allergic rhinitis: the possible role of leukotrienes. Ann Allergy Asthma Immunol 2003;91:131–140.
- 46, , , , , et al. Minimal persistent inflammation is also present in patients with seasonal allergic rhinitis. J Allergy Clin Immunol 2000;105(1 Pt 1):54–57.
- 47. Immunotherapy of asthma using CpG oligodeoxynucleotides. Immunol Res 2007;39:279–286.